SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Tuesday, February 28, 2023 at 5:00 PM ET to report its fourth quarter and full year 2022 financial results and provide a corporate update.
In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer and autoimmune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Matthew Guido
Stern Investor Relations, Inc.
212-362-1200
matthew.guido@sternir.com
New "GIM" method tops MIB global leaderboard, offering the industry a scalable way to inspect…
HOTWORX Shares Expert Guidance on Building Sustainable Fitness Goals That Go Beyond Just Working OutNEW…
Leading Dog Training Franchise Expands Human Level Fitness Tracking to Select LocationsLOS ANGELES, Dec. 18,…
AdventHealth's David Banks, Savannah Bananas' Tyler Gillum, AMA's John Whyte, MD, MPH and Lenox Hill…
Practice of the Year and Innovator of the Year honorees recognized for patient-centered care, operational…
As Chief Executive Officer of Alexso, Inc., a nationwide pharmaceutical distributor, Farahmand has earned recognition…